Your session is about to expire
← Back to Search
Nyxol Eye Drops + Low-Dose Pilocarpine Eye Drops for Presbyopia (VEGA-2 Trial)
VEGA-2 Trial Summary
This trial will test a new eye treatment to improve near vision in people with presbyopia.
VEGA-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.VEGA-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a known allergy or cannot take medications that block alpha- and/or beta-adrenergic receptors.You have a known allergy or a medical reason that makes it unsafe for you to take certain medications that affect your nervous system.You are currently using any eye drops or medications for dry eyes.You have previously taken part in a study using Nyxol for treating presbyopia.You have had an eye injury in the past 6 months.You have a history of eye conditions that have affected your pupil or iris, either due to surgery, injury, or other non-traumatic causes.
- Group 1: Nyxol + low dose pilocarpine
- Group 2: Nyxol + low dose pilocarpine vehicle
- Group 3: Placebo + low dose pilocarpine
- Group 4: Placebo + low dose pilocarpine vehicle
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you elucidate the dangers of administering Nyxol and low dose pilocarpine to patients?
"With prior clinical data attesting to its safety, Nyxol + low dose pilocarpine was evaluated and assigned a score of 3."
Are any vacancies still available for enrollment in this research?
"Clinicaltrials.gov reports that the recruitment process for this medical study is still ongoing; it was initially posted on December 22nd 2022 with its most recent edit taking place on February 24th 2023."
Does this research program accept elderly participants?
"This medical trial has a 40-year old minimum age limit and an upper threshold of 64 years."
How many participants are eligible to join this clinical research program?
"Ocuphire Pharma, Inc. will be conducting the trial at two sites: Phoenix in Arizona and Azusa in California. In order to successfully complete this study, 320 patients meeting all inclusion criteria must participate."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger